IQV

IQVIA's stock (IQV) has shown an upward trend, increasing by 24.96% over the last 12 months and a year-to-date return of 14.68% as of October 5, 2026, with the stock price at $268.99 per share on September 29, 2026. Significant positive events include strong Q2 2026 results reported on July 28, 2026, surpassing expectations with revenue of $4.37 billion and adjusted diluted EPS of $3.15, leading to raised full-year guidance. On October 7, 2026, IQVIA introduced new Life Science Models, a suite of AI-powered tools for predicting clinical trial outcomes and enhancing drug development. Analyst sentiment has been largely positive, with some firms upgrading IQVIA to a "strong-buy" rating. However, recent bearish technical indicators include the 10-day RSI Indicator moving out of overbought territory on September 4, 2026, and the Moving Average Convergence Divergence Histogram (MACD) turning negative on October 1, 2026.